Unknown

Dataset Information

0

Gene therapy using an ortholog of human fragile X mental retardation protein partially rescues behavioral abnormalities and EEG activity.


ABSTRACT: Fragile X syndrome (FXS), a neurodevelopmental disorder with no known cure, is caused by a lack of expression of the fragile X mental retardation protein (FMRP). As a single-gene disorder, FXS is an excellent candidate for viral-vector-based gene therapy, although that is complicated by the existence of multiple isoforms of FMRP, whose individual cellular functions are unknown. We studied the effects of rat and mouse orthologs of human isoform 17, a major expressed isoform of FMRP. Injection of neonatal Fmr1 knockout rats and mice with adeno-associated viral vectors (AAV9 serotype) under the control of an MeCP2 mini-promoter resulted in widespread distribution of the FMRP transgenes throughout the telencephalon and diencephalon. Transgene expression occurred mainly in non-GABAergic neurons, with little expression in glia. Early postnatal treatment resulted in partial rescue of the Fmr1 KO rat phenotype, including improved social dominance in treated Fmr1 KO females and partial rescue of locomotor activity in males. Electro-encephalogram (EEG) recordings showed correction of abnormal slow-wave activity during the sleep-like state in male Fmr1 KO rats. These findings support the use of AAV-based gene therapy as a treatment for FXS and specifically demonstrate the potential therapeutic benefit of human FMRP isoform 17 orthologs.

SUBMITTER: Hooper AWM 

PROVIDER: S-EPMC8399347 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC4052976 | biostudies-literature
| S-EPMC2844383 | biostudies-literature
2016-06-01 | GSE51649 | GEO
2016-06-01 | E-GEOD-51649 | biostudies-arrayexpress
| S-EPMC2992329 | biostudies-other
2009-12-16 | GSE19457 | GEO
| S-EPMC6915005 | biostudies-literature
| S-EPMC2206605 | biostudies-literature
| S-EPMC398353 | biostudies-other
| S-EPMC407820 | biostudies-other